CoChat
Sign Up
Cited by 22

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors

Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., Puglisi, F., Pignata, S.·2021·Cancer Treatment Reviews
DOI 10.1016/j.ctrv.2021.102298
Open this paper in CoChat — free account

Abstract

After more than 30 years of a one-size-fits-all approach in the management of advanced ovarian cancer, in 2018 the SOLO1 trial results have introduced a new era of personalized medicine. A deeper knowledge of ovarian cancer biology and the development of new drugs targeting specific molecular pathways have led to biomarker-driven phase 3 trials with practice changing results. Thereafter, platinum-based combinations are no longer the only therapeutic options available in first line setting and poly-ADP ribose polymerase inhibitors maintenance therapy has become the mainstay in patients with tumor harboring a homologous recombination defect. However, most of the recent therapeutic breakthroughs regard high grade serous carcinoma, the most frequent ovarian cancer subtype, and only few improvements have occurred in the management of less common histotypes. Moving towards the next challenges, we aimed to investigate and review new potential molecular targets in ovarian cancer, according to histotype, starting from promising molecular drivers and matched drugs that have been investigated in early and late-stage clinical trials or conceptualized in preclinical studies.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ctrv.2021.102298

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 65

  1. Bray, 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Can J Clin, 68, 394
  2. Menon, 2021, Ovarian Cancer Population Screening and Mortality after Long-Term Follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomised Controlled Trial, Lancet, 397, 2182, 10.1016/S0140-6736(21)00731-5 · DOI · Paper page
  3. Lee, 2018, Changes in ovarian cancer survival during the 20 years before the era of targeted therapy, BMC Cancer, 18, 601, 10.1186/s12885-018-4498-z · DOI
  4. Moore, 2018, Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer, N. Engl. J. Med., 379, 2495, 10.1056/NEJMoa1810858 · DOI · Paper page
  5. González-Martín, 2019, Niraparib in patients with newly diagnosed advanced ovarian cancer, N. Engl. J. Med., 381, 2391, 10.1056/NEJMoa1910962 · DOI
  6. Ray-Coquard, 2019, Olaparib plus bevacizumab as first-line maintenance in ovarian cancer, N Engl J Med, 381, 2416, 10.1056/NEJMoa1911361 · DOI
  7. Bartoletti, 2021, Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices, ESMO Open, 6, 100135, 10.1016/j.esmoop.2021.100135 · DOI
  8. Baert, 2021, The systemic treatment of recurrent ovarian cancer revisited, Ann Oncol, 32, 710, 10.1016/j.annonc.2021.02.015 · DOI
  9. Cancer Genome Atlas Research Network Integrated Genomic Analyses of Ovarian Carcinoma. Nature 2011, 474, 609–615, 10.1038/nature10166. · DOI · Paper page
  10. Murai, 2017, Targeting DNA repair and replication stress in the treatment of ovarian cancer, Int J Clin Oncol, 22, 619, 10.1007/s10147-017-1145-7 · DOI
  11. Karnitz, 2015, Molecular pathways: targeting ATR in cancer therapy, Clin Cancer Res, 21, 4780, 10.1158/1078-0432.CCR-15-0479 · DOI
  12. Lheureux, 2021, Adavosertib plus Gemcitabine for Platinum-Resistant or Platinum-Refractory Recurrent Ovarian Cancer: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial, The Lancet, 397, 281, 10.1016/S0140-6736(20)32554-X · DOI
  13. Oza, 2020, A Biomarker-Enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-Sensitive TP53-Mutant Ovarian Cancer, Clin Cancer Res, 26, 4767, 10.1158/1078-0432.CCR-20-0219 · DOI · Paper page
  14. Westin SN, Coleman RL Fellman BM, Yuan Y, Sood AK, Soliman PT, et al. EFFORT: EFFicacy Of Adavosertib in Parp ResisTance: A Randomized Two-Arm Non-Comparative Phase II Study of Adavosertib with or without Olaparib in Women with PARP-Resistant Ovarian Cancer. JCO 2021, 39, 5505–5505, 10.1200/JCO.2021.39.15_suppl.5505. · DOI
  15. Konstantinopoulos, 2020, Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial, Lancet Oncol, 21, 957, 10.1016/S1470-2045(20)30180-7 · DOI
  16. Lee J-M, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ et al. Prexasertib, a Cell Cycle Checkpoint Kinase 1 and 2 Inhibitor, in BRCA Wild-Type Recurrent High-Grade Serous Ovarian Cancer: A First-in-Class Proof-of-Concept Phase 2 Study. The Lancet Oncology 2018, 19, 207–215, 10.1016/S1470-2045(18)30009-3. · DOI
  17. Siu MKY, Kong DSH, Chan HY, Wong ESY, Ip PPC, Jiang L et al. Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome. PLOS ONE 2012, 7, e47201, 10.1371/journal.pone.0047201. · DOI
  18. Toffoli, 1997, Overexpression of folate binding protein in ovarian cancers, Int J Can, 74, 193, 10.1002/(SICI)1097-0215(19970422)74:2<193::AID-IJC10>3.0.CO;2-F · DOI
  19. Vergote I, Armstrong D, Scambia G, Teneriello M, Sehouli J, Schweizer C et al. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. JCO 34 (2016) 2271–2278, 10.1200/JCO.2015.63.2596. · DOI
  20. Naumann RW, Gilbert L, Miller AM, Ma H, Ghamande SA, Vergote I. A Randomized Double-Blind Phase III Trial Comparing Vintafolide plus Pegylated Liposomal Doxorubicin (PLD) versus PLD plus Placebo in Patients with Platinum-Resistant Ovarian Cancer (PROCEED). JCO 2013, 31, TPS5613–TPS5613, 10.1200/jco.2013.31.15_suppl.tps5613. · DOI
  21. Moore, 2021, Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I, Ann Oncol, 10.1016/j.annonc.2021.02.017 · DOI
  22. Gay, 2017, Giving AXL the axe: targeting AXL in human malignancy, Br J Can, 116, 415, 10.1038/bjc.2016.428 · DOI
  23. Lozneanu, 2016, Computational and immunohistochemical analyses highlight AXL as a Potential prognostic marker for ovarian cancer patients, Anticancer Res, 36, 4155
  24. Macleod, 2005, Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer, Cancer Res, 65, 6789, 10.1158/0008-5472.CAN-04-2684 · DOI
  25. Quinn, 2019, Therapeutic inhibition of the receptor tyrosine kinase AXL improves sensitivity to platinum and taxane in ovarian cancer, Mol Can Ther, 18, 389, 10.1158/1535-7163.MCT-18-0537 · DOI
  26. Chan, 2008, Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers, Gynecol Oncol, 109, 370, 10.1016/j.ygyno.2008.02.006 · DOI
  27. Jones, 2010, Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma, Science, 330, 228, 10.1126/science.1196333 · DOI
  28. Farley JH, Brady WE, Fujiwara K, Nomura H, Yunokawa M, Tokunaga H et al. A Phase II evaluation of temsirolimus in combination with carboplatin and paclitaxel followed by temsirolimus consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary. JCO 2016;34:5531–5531, 10.1200/JCO.2016.34.15_suppl.5531. · DOI
  29. Chan, 2018, A Phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG Oncology/gynecologic oncology group study (GOG-254), Gynecol Oncol, 150, 247, 10.1016/j.ygyno.2018.05.029 · DOI
  30. Glasspool, 2020, 596 A Randomised Phase II Study of Nintedanib (BIBF1120) Compared to Chemotherapy in Patients with Recurrent Clear Cell Carcinoma of the Ovary or Endometrium. (NICCC/ENGOT-OV36), Int J Gynecol Can, 30
  31. Yamashita, 2013, Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis, PLoS ONE, 8, e57724, 10.1371/journal.pone.0057724 · DOI
  32. Konstantinopoulos, 2018, Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001), Gynecol Oncol, 150, 9, 10.1016/j.ygyno.2018.04.572 · DOI
  33. Wolf, 2020, Capmatinib in MET exon 14–mutated or MET-amplified non–small-cell lung cancer, N Engl J Med, 383, 944, 10.1056/NEJMoa2002787 · DOI
  34. Oda, 2018, Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management, Gynecol Oncol, 151, 381, 10.1016/j.ygyno.2018.09.001 · DOI
  35. Marabelle, 2020, Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, 1353, 10.1016/S1470-2045(20)30445-9 · DOI · Paper page
  36. Rousseau, 2021, The spectrum of benefit from checkpoint blockade in hypermutated tumors, N Engl J Med, 384, 1168, 10.1056/NEJMc2031965 · DOI
  37. Matulonis, 2019, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the Phase II KEYNOTE-100 study, Ann Oncol, 30, 1080, 10.1093/annonc/mdz135 · DOI
  38. Hamanishi, 2015, Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer, JCO, 33, 4015, 10.1200/JCO.2015.62.3397 · DOI
  39. Ledermann JA, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall LM et al. Avelumab in Combination with and/or Following Chemotherapy vs Chemotherapy Alone in Patients with Previously Untreated Epithelial Ovarian Cancer: Results from the Phase 3 Javelin Ovarian 100 Trial.; SGO, March 29 2020. · DOI
  40. Moore, 2021, Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39), JCO, JCO.21.00306
  41. Ngoi, 2020, A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA), Int J Gynecol Can, 30, 1239, 10.1136/ijgc-2020-001604 · DOI
  42. Seidman, 2004, The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin, Int J Gynecol Pathol, 23, 41, 10.1097/01.pgp.0000101080.35393.16 · DOI
  43. Lee, 2015, Safety of fertility-sparing surgery in primary mucinous carcinoma of the ovary, Cancer Res Treat, 47, 290, 10.4143/crt.2014.004 · DOI
  44. Gore, 2019, An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (MEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor, Gynecol Oncol, 153, 541, 10.1016/j.ygyno.2019.03.256 · DOI
  45. Gorringe, 2020, Therapeutic options for mucinous ovarian carcinoma, Gynecol Oncol, 156, 552, 10.1016/j.ygyno.2019.12.015 · DOI
  46. McAlpine, 2009, HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy, BMC Cancer, 9, 10.1186/1471-2407-9-433 · DOI
  47. Jain, 2012, Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location, J Natl Compr Canc Netw, 10, 1076, 10.6004/jnccn.2012.0113 · DOI
  48. Anglesio, 2013, Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas, J Pathol, 229, 111, 10.1002/path.4088 · DOI
  49. Matsuo, 2018, Trends of low-grade serous ovarian carcinoma in the United States, J Gynecol Oncol, 29
  50. C DP, G T, D S, S L, C P, M DN, et al. Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. Can Treat Rev 2014;41:136–143, 10.1016/j.ctrv.2014.12.003. · DOI
  51. Escobar, 2013, Quantification of ER/PR expression in ovarian low-grade serous carcinoma, Gynecol Oncol, 128, 371, 10.1016/j.ygyno.2012.10.013 · DOI
  52. Colon-Otero G, Weroha SJ, Zanfagnin V, Foster NR, Asmus E, Wahner Hendrickson AE et al. Results of a phase 2 trial of ribociclib and letrozole in patients with either relapsed estrogen receptor (ER)-positive ovarian cancers or relapsed ER-positive endometrial cancers. JCO 2019;37:5510–5510, 10.1200/JCO.2019.37.15_suppl.5510. · DOI
  53. McLachlan, 2016, Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary, Pharmacogenomics, 17, 1353, 10.2217/pgs.16.24 · DOI
  54. Turashvili, 2018, BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary, Histopathology, 73, 438, 10.1111/his.13651 · DOI
  55. Moujaber, 2018, BRAF mutations in low-grade serous ovarian cancer and response to BRAF inhibition, JCO Precis Oncol, 1, 10.1200/PO.17.00221 · DOI
  56. Salama, 2020, Dabrafenib and trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H, JCO, 38, 3895, 10.1200/JCO.20.00762 · DOI
  57. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. Int J Gynecol Cancer 2014, 24, S55-60, 10.1097/IGC.0000000000000228. · DOI
  58. Gotoh, 2019, Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma, Nat Commun, 10, 4965, 10.1038/s41467-019-12985-x · DOI
  59. Powell MA, Filiaci VL, Hensley ML, Huang HQ, Moore KN, Tewari KS et al. A Randomized Phase 3 Trial of Paclitaxel (P) plus Carboplatin (C) versus Paclitaxel plus Ifosfamide (I) in Chemotherapy-Naive Patients with Stage I-IV, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. JCO 2019;37: 5500–5500, 10.1200/JCO.2019.37.15_suppl.5500. · DOI
  60. Rottmann, 2020, HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy, Mod Pathol, 33, 118, 10.1038/s41379-019-0358-x · DOI
  61. Menderes, 2017, SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression, Clin Can Res, 23, 5836, 10.1158/1078-0432.CCR-16-2862 · DOI
  62. Nicoletti, 2015, T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2, Clin Exp Metastasis, 32, 29, 10.1007/s10585-014-9688-8 · DOI
  63. McGee, 2017, Fifth ovarian cancer consensus conference: individualized therapy and patient factors, Ann Oncol, 28, 702, 10.1093/annonc/mdx010 · DOI
  64. Sieh, 2013, Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study, Lancet Oncol, 14, 853, 10.1016/S1470-2045(13)70253-5 · DOI
  65. Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew Y-E, Rowley SM, et al. Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget 2015;6:37663–37677, 10.18632/oncotarget.5438. · DOI

Cited by

Sorted by citations

See all 22

Metadata

Authors
Bartoletti, M., Musacchio, L., Giannone, G., Tuninetti, V., Bergamini, A., Scambia, G., Lorusso, D., Valabrega, G., Mangili, G., Puglisi, F., & Pignata, S.
Venue
Cancer Treatment Reviews
Publisher
Elsevier BV
Published
2021-12
Volume
101
Pages
102298
ISSN
0305-7372
DOI
10.1016/j.ctrv.2021.102298
Cited by
22
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review